Heterogeneity of Cardiovascular Effects of Second‐Line Glucose‐Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk

Heterogeneity of Cardiovascular Effects of Second‐Line Glucose‐Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium–glucose cotransporter‐2 inhibitors (SGLT2is) have favorable cardiovascular outcomes compared with dipeptidyl peptidase‐4 inhibitors (DPP4is) and sulfonylureas in adults with type 2 diabetes and high cardiovascular risk. How t...

Full description

Saved in:
Bibliographic Details
Main Authors: Yihong Deng, Eric C. Polley, Jeph Herrin, Kavya S. Swarna, David M. Kent, Joseph S. Ross, Bradley A. Maron, Mindy M. Mickelson, Rozalina G. McCoy
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
cardiovascular disease risk
comparative effectiveness
heart failure
heterogeneous treatment effects
major adverse cardiovascular events
target trial
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.040217
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.040217

Similar Items